Aurora Cannabis (NASDAQ:ACB - Get Free Report) is expected to be releasing its Q3 2025 earnings data before the market opens on Wednesday, February 5th. Analysts expect Aurora Cannabis to post earnings of ($0.09) per share and revenue of $80.01 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.
Aurora Cannabis (NASDAQ:ACB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.15. Aurora Cannabis had a negative return on equity of 2.19% and a negative net margin of 17.47%. On average, analysts expect Aurora Cannabis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Aurora Cannabis Stock Performance
Shares of ACB stock traded up $0.88 on Thursday, hitting $6.25. The company had a trading volume of 21,123,756 shares, compared to its average volume of 4,483,580. The firm has a market cap of $342.88 million, a P/E ratio of -8.22 and a beta of 1.85. Aurora Cannabis has a twelve month low of $2.84 and a twelve month high of $9.35. The company has a 50-day moving average price of $4.24 and a 200-day moving average price of $5.16. The company has a quick ratio of 1.88, a current ratio of 3.83 and a debt-to-equity ratio of 0.07.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on ACB shares. TD Securities raised shares of Aurora Cannabis to a "strong-buy" rating in a report on Thursday, December 12th. TD Cowen began coverage on shares of Aurora Cannabis in a report on Wednesday, December 11th. They issued a "buy" rating for the company.
Check Out Our Latest Stock Analysis on ACB
About Aurora Cannabis
(
Get Free Report)
Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.
See Also
Before you consider Aurora Cannabis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurora Cannabis wasn't on the list.
While Aurora Cannabis currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
